An Evidence-Based Perspective on Risk, Limits, and Patient Understanding

Recently, a widely circulated media statement in China sparked considerable attention—and concern—within the vascular community. A physician described cyanoacrylate treatment for varicose veins as “a single injection that permanently solves the problem.” The message was simple, compelling, and easy to understand. It was also, in many ways, misleading.

The concern is not about the existence of the technique itself. Cyanoacrylate closure is a recognized method in modern venous intervention. The concern lies in something more fundamental: the gap between how a treatment is described and how it actually behaves within the body.

From a patient’s perspective, the appeal is obvious. “One injection” suggests precision. “Permanent” suggests certainty. Together, they form a narrative that aligns perfectly with contemporary expectations of minimally invasive medicine. But biological systems do not follow narrative simplicity. They follow physiology.

Cyanoacrylate is often introduced as an adhesive—a substance that “seals” a vein. While convenient, this description is incomplete. Once delivered into the vascular system, cyanoacrylate rapidly polymerizes and initiates a cascade of biological events, including endothelial injury, inflammation, and subsequent fibrosis. Its effect is not simply mechanical closure, but a reaction-driven transformation of the vessel.

Importantly, cyanoacrylate is approved for truncal vein closure—not for varicose tributaries. In other words, by design, it addresses a pathway, not the full expression of the disease. This distinction, however, is not always clearly communicated to patients, leaving many to believe they are receiving a complete solution.

This is precisely where concern begins. When a treatment depends on biological response, variability becomes inevitable. Clinical studies and systematic reviews have documented a spectrum of outcomes associated with cyanoacrylate, including phlebitis-like reactions, hypersensitivity, granuloma formation, and endovenous glue-induced thrombosis (EGIT). These are not rare anomalies, but recognized patterns emerging from real-world practice.

Large-scale data further reinforces this point. A nationwide survey in Japan involving over 24,000 procedures reported thromboembolic events, inflammatory complications, and a death associated with pulmonary embolism. Additional analyses of international regulatory databases have identified hundreds of serious adverse events, including thrombotic and immune-related complications. While these events remain relatively uncommon, they illustrate an important truth: the behavior of this material is not entirely predictable.

Individual case reports offer even greater clarity. Instances of foreign body granuloma, abscess formation, and infections requiring surgical removal of treated veins have been described. There are also reports of severe thrombotic progression following treatment. These cases are not simply complications; they are expressions of how a reactive material interacts with a living system over time.

What ultimately distinguishes cyanoacrylate is not that it is a foreign material, but that it is an active one. Most implants are designed to remain biologically quiet. Cyanoacrylate, by contrast, works by initiating and sustaining a biological response. It is also deployed within the vascular system—a dynamic environment defined by flow, pressure, and systemic connectivity. In this setting, local reactions can extend beyond their point of origin, interacting with the broader circulatory system.

Time adds another dimension. Many widely accepted implants are supported by decades of long-term data. Cyanoacrylate, in contrast, represents a relatively recent application within the venous system. While short- and mid-term outcomes are increasingly well characterized, its long-term behavior as a non-degradable, reaction-initiating material remains an area of ongoing observation.

The issue, therefore, is not whether cyanoacrylate “works.” It clearly does. The issue is how it is understood—and how it is presented. When a complex biological process is reduced to a simplified message, the uncertainty does not disappear. It is merely transferred, often to the patient.

Cyanoacrylate does not simply close a vein. It introduces a material that interacts with blood, vessel wall, and immune system in a dynamic and irreversible way. To describe this as “one injection” is not just an oversimplification. It is a distortion of mechanism.

Can Glue Ever Fit CHIVA?

Perhaps not in its current form—but the question itself is worth asking. Cyanoacrylate represents a shift toward less invasive, non-thermal intervention, and its ability to act without extensive dissection or energy delivery points to a future where treatment may become more precise and targeted. If its use could evolve from segmental occlusion toward controlled, selective intervention, it may begin to align—at least in part—with the hemodynamic principles that CHIVA emphasizes.

The real opportunity, therefore, may not lie in adapting glue as it is, but in what it suggests: that venous treatment could move beyond broad elimination toward finer modulation. In that sense, glue does not yet fit CHIVA—but it may be pointing in the same direction.

A treatment does not become simple because it is described simply.
And in medicine, clarity should never come at the cost of truth.

For patients:
If you are considering “glue” treatment for varicose veins, it is reasonable to ask:

• What part of my veins will this treatment address?
• Will additional treatment be needed?
• What are the possible reactions after the procedure?

Understanding these questions is not about doubt—it is about making an informed decision.